Gattinoni et al. later demonstrated that mouse tumor-specific anti-gp100 CD8+ T cells treated with 4,6-disubstituted pyrrolopyrimidine (TWS119), a pharmacologic inhibitor of the glycogen synthase kinase 3β (GSK-3β), could generate a TSCM phenotype [7]. This evidence concerns the gene CD8A and neoplasm.